Accepts applications
Can I apply?
Accepts applications
The funder's latest Form 990-PF says it accepts applications. Read the instructions below before you write.
- How to apply
- Deadlines
The funder's latest Form 990-PF says it accepts applications. Read the instructions below before you write.
Application policy: Accepts applications, as stated on the FY2024 return.
Application guidance comes from the funder's own Form 990-PF, Part XV (the section where a private foundation says how to apply), shown as filed. It is the funder's words, not ours. These fields are free text and the IRS form cuts them short. Filers sometimes put whole sentences in the contact-name box. Shown exactly as filed.
Giving by year
Total assets by year
| Year | Form | Revenue | Expenses | Giving | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2024 | 990-PF | $8,238,171 | $3,493,538 | $2,169,889 | $35,041,767 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 13% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| University of PittsburghPittsburgh, PA | Escolar's Grant "Treatment of KD Using Gene Therapy: Continuation" | $174,821 | 2019 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Paul Rosenau | President | 5.00 | $0 |
| Gillian Hauboldt | Treasurer | 2.00 | $0 |
| Mary Kay Delvo Amanda Post | Secretary | 2.00 | $0 |
| Heather Techmeier | Director |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| $33,535,088 |
| FY2023 | 990-PF | $2,316,796 | $2,493,037 | $1,751,191 | $30,291,573 | $28,951,124 |
| FY2022 | 990-PF | $1,612,643 | $1,884,423 | $1,248,984 | $30,473,177 | $29,119,327 |
| FY2021 | 990-PF | $1,957,355 | $2,538,328 | $2,045,756 | $30,431,598 | $29,624,200 |
| FY2020 | 990-PF | $1,406,227 | $2,592,511 | $2,288,582 | $31,834,443 | $31,460,175 |
| FY2019 | 990-PF | $2,777,190 | $2,019,601 | $1,816,401 | $33,862,722 | $33,341,242 |
| FY2018 | 990-PF | $231,817 | $999,548 | $767,898 | $33,105,401 | $32,082,378 |
| FY2017 | 990-PF | $4,514,351 | $1,546,271 | $1,465,233 | $33,872,948 | $33,628,258 |
| FY2016 | 990-PF | $2,882,909 | $3,747,274 | $3,675,287 | $30,905,140 | $29,740,219 |
| University of IllinoisChicago, IL |
| Vesicular Delivery of GALC for ERT of KD |
| $158,853 |
| 2020 |
| UNIVERSITY OF ILLINOISURBANA, IL | RESEARCH TO BETTER TREAT KD | $157,500 | 2017 |
| UNIVERSITY OF ILLINOISURBANA, IL | RESEARCH TO BETTER TREAT KD | $157,500 | 2016 |
| Biomedical Research Institute of NJCedar Knools, NJ | Psychosine Profiling and Evaluation as a Therapeutic for KD | $149,154 | 2024 |
| University of IllinoisChicago, IL | Vesicular Delivery of GALC for ERT of KD | $148,723 | 2021 |
| University of IllinoisChicago, IL | Vesicular Delivery of GALC for ERT of KD | $142,423 | 2022 |
| Biomedical Research Institute of NJMorristown, NJ | Development of Pharmacological Chaperone Therapy for KD Grant | $140,024 | 2019 |
| CHILDREN'S HOSPITAL OF PITTSBURGHPITTSBURGH, PA | RESEARCH TO BETTER TREAT KD & FDA | $136,121 | 2017 |
| Biomedical Research Institute of NJMorristown, NJ | Development of Pharmacological Chaperone Therapy for KD Grant | $131,574 | 2020 |
| Biomedical Research Institute of NJCedar Knools, NJ | Psychosine Profiling and Evaluation as a Therapeutic for KD | $129,834 | 2023 |
| Thomas Jefferson UniversityPhiladelphia, PA | Optimizing Treatment of the Mouse Model of KD for Translation Into Human Trial Grant | $127,949 | 2019 |
| THOMAS JEFFERSON UNIVERSITYPHILADELPHIA, PA | MOUSE MODEL TRANSLATION INTO HUMAN | $125,707 | 2018 |
| University of PittsburghPittsburgh, PA | Disclosure of Newborn Screening Results for KD in Pennsylvania | $125,000 | 2024 |
| University of IllinoisChicago, IL | A Maladaptive Pathway Involved In Early Pathogenesis of KD | $125,000 | 2024 |
| Nationwide Children's HospitalColumbus, OH | Evaluation of In Utero Gene Therapy in Canine KD | $125,000 | 2024 |
| University of BuffaloAmherst, NY | Modulating Oligodendroglial NFkB as a Therapeutic Strategy for KD | $125,000 | 2024 |
| University of IllinoisChicago, IL | Immune Responses in Peripheral Nerves after Hematopoietic Stem Cell Transplants for KD | $125,000 | 2023 |
| University of MinnesotaMinneapolis, MN | GenoKrabbe: A Comprehensive Genotype-Phenotype Database for KD | $125,000 | 2024 |
| Biomedical Research Institute of NJCedar Knools, NJ | Psychosine Profiling and Evaluation as a Therapeutic for KD | $124,756 | 2022 |
| KrabbeConnectRosemount, MN | Parent-Reported Disease Burden in Infantile & Late Infantile KD | $123,982 | 2024 |
| KrabbeConnectRosemount, MN | Parent-Reported Disease Burden in Infantile & Late Infantile KD | $122,708 | 2023 |
| BIOMEDICAL RESEARCH INSTITUTE OF NJMORRISTOWN, NJ | PHARMACOLOGICAL CHAPERONE THERAPY | $121,974 | 2018 |
| University of BuffaloAmherst, NY | Innovative Model Systems to Study & Boost Innate Immunity in KD | $121,666 | 2021 |
| UNIVERSITY OF NORTH DAKOTACHAPEL HILL, NC | RESEARCH FOR 3 GENE THERAPIES BMT | $111,106 | 2016 |
| 40.00 |
| $188,041 |
| Dr Gabriel Cohn | Director | 40.00 | $175,000 |
| Julie Mccarrier | Director | 2.00 | $0 |
| Li Ou | Director | 2.00 | $0 |
| Phil Christianson | Director | 2.00 | $0 |
| Marci Sontag | Director | 2.00 | $0 |
| Karlita Blackwell | Director | 2.00 | $0 |
Only shared inboxes and organization phone lines that appear in public filings are shown here. Contact details for named individuals are never published, even though the filing itself is public.
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990-PF · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202402619349100410
Form 990-PF · FY2022 · period ending Dec 31, 2022
Filing id 202312569349101016
Form 990-PF · FY2021 · period ending Dec 31, 2021
Filing id 202201369349105335
Form 990-PF · FY2020 · period ending Dec 31, 2020
Filing id 202133149349100018
Form 990-PF · FY2019 · period ending Dec 31, 2019
Filing id 202011969349100146
Form 990-PF · FY2018 · period ending Dec 31, 2018
Filing id 201931359349103913
Form 990-PF · FY2017 · period ending Dec 31, 2017
Filing id 201831299349100138
Form 990-PF · FY2016 · period ending Dec 31, 2016
Filing id 201701319349102740
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.